Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...
Improvements include portions of Elizabeth, 29th, and Court Streets, along with most of Bonforte Boulevard. Work should start ...
RANDOLPH COUNTY, N.C. (WGHP) — A Randolph County couple is preparing to lay their 9-year-old daughter to rest after she died ...
Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...
Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.
Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...
Eli Lilly's profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast.
The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for ...
While it may seem strange that politics could impact the price of popular weight loss drugs, it is a definite possibility.
Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.
Eli Lilly reported mixed fourth-quarter results on Thursday, surpassing earnings expectations but falling short of sales ...
Revenue in Q4 2024 increased 45% to $13.53 billion driven by volume growth from Mounjaro and Zepbound. Non-incretin revenue(i) grew by 20% compared to Q4 2023. Pipeline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results